Table 2 Glucose homeostasis and insulin sensitivity at baseline and after the intervention. The significance threshold for adjusted p-values using the Holm-Bonferroni correction is 0.05
Placebo | Pio | Omega-3 | Pio& Omega-3 | |
|---|---|---|---|---|
HbA1c (IFCC, mmol/mol) | ||||
Baseline | 52 (48, 56) | 52 (47, 54) | 50 (47, 55) | 49 (44, 53) |
Week 24 | 49 (48, 51) | 49 (46, 55) | 58 (51, 73) | 48 (46, 53) |
∆ | 0 (−5, 1) | 0 (−5, 1) | 7 (1, 13)a, b | 0 (−3, 2) |
∆ (%) | 0.0 (−8.9, 2.1) | 0.0 (−7.6, 1.9) | 14.7 (2.6, 22.1)a, b | 0.0 (−6.2, 3.9) |
Fasting blood glucose (mmol/l) | ||||
Baseline | 7.31 (6.40, 8.27) | 7.48 (7.15, 8.47) | 7.67 (6.53, 8.87) | 7.10 (6.51, 8.18) |
Week 24 | 7.26 (5.99, 8.17) | 7.39 (6.79, 8.00) | 9.10 (7.34, 10.50) | 7.22 (6.59, 8.44) |
∆ | −0.10 (−1.32, 0.80) | −0.25 (−0.78, 0.01) | 1.07 (0.18, 2.02)b | 0.05 (−0.51, 0.47) |
∆ (%) | −1.2 (−18.1, 12.4) | −3.7 (−8.4, 0.1) | 17.0 (1.6, 25.2)b | 0.8 (−5.6, 7.4) |
M (mg/kg.min−1) | ||||
Baseline | 3.42 (2.38, 3.97) | 2.51 (2.12, 4.10) | 2.66 (2.15, 3.34) | 3.21 (2.52, 3.68) |
Week 24 | 2.79 (1.89, 3.09) | 2.93 (2.69, 4.47) | 2.33 (1.18, 3.41) | 3.55 (3.08, 4.34)c |
∆ | −0.60 (−1.24, 0.60) | 0.29 (−0.34, 1.30) | −0.58 (−1.25, −0.13) | 0.53 (−0.20, 0.92) |
∆ (%) | −17.1 (−38.1, 17.2) | 12.0 (−13.0, 52.7) | −21.2 (−41.0, 1.9) | 14.6 (−6.2, 40.3) |